Skip to content
Clinical Trials – home
Not recruiting

Evaluation of the interaction between finasteride and tadalafil in healthy male volunteers

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The study involves healthy male volunteers and examines the interaction between two oral tablets: tadalafil, a medication commonly used for erectile dysfunction, and finasteride, a medication often prescribed for enlarged prostate or hair loss. The purpose of the study is to evaluate how each drug affects the absorption of the other when taken together.

Participants are randomly assigned to receive the medicines in different sequences, with each person taking one tablet alone, the other tablet alone, and then both tablets together, while fasting (meaning no food is eaten before taking the medication). This “cross‑over” design allows each volunteer to serve as his own comparison. The study includes a single dose of each treatment, monitoring for safety and how well the drugs are tolerated, and it records any changes in how quickly and how much of each drug enters the bloodstream.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization and Treatment Sequence Assignment

    After joining the study, you will be randomly assigned to a specific order in which the medications are taken. The order may include taking tadalafil alone, finasteride alone, or both drugs together.

  2. Step 2

    First Dosing Visit

    You will arrive at the clinic after an overnight fast, meaning no food or drink (except water) for at least 8 hours.

    According to the assigned sequence, you will take a single 5 mg tablet of tadalafil, a single 5 mg tablet of finasteride, or both tablets together. The tablets are taken by mouth.

    You will remain fasting for the period specified by the study staff and may have blood samples taken to assess how the drug is absorbed.

  3. Step 3

    Washout Period

    After the first dose, you will wait for a washout period, during which no study medication is taken. This allows the previous drug to leave your body before the next dose.

  4. Step 4

    Second Dosing Visit

    You will again fast for at least 8 hours before arriving at the clinic.

    You will take the next medication according to the randomized order: either the single tablet of tadalafil, the single tablet of finasteride, or both tablets together.

    Fasting will be continued as instructed, and additional safety checks may be performed.

  5. Step 5

    Second Washout Period

    A second washout period will follow, during which no study medication is taken.

  6. Step 6

    Third Dosing Visit

    You will fast for at least 8 hours before the final clinic visit.

    You will receive the remaining medication regimen (the one not yet taken), either a single tablet of tadalafil, a single tablet of finasteride, or both tablets together.

    Fasting will be maintained as directed, and final safety assessments will be completed.

  7. Step 7

    Safety and Tolerability Assessments

    Throughout the study, you will be asked to report any side effects or discomfort.

    The study team will perform simple examinations to evaluate safety and how well you tolerated the medications.

Who can join the trial?

9 criteria

  • Be a healthy male who is between 18 and 60 years old at the time of screening.
  • Have a body‑mass index (BMI) from 18.5 to 30.0 kg/m², which is a calculation of weight divided by height squared.
  • Be a non‑smoker or a former smoker who stopped smoking at least 3 months before the first dose.
  • Identify as Caucasian race.
  • Be willing and able to follow all study procedures, including any contraception rules, and sign a written informed consent form.
  • Have a medical history that shows no important health problems.
  • Have a physical examination that shows no important health problems.
  • Have an ECG (a test that records the heart’s electrical activity) that shows no important heart problems.
  • Have all laboratory screening results (blood, urine, etc.) within the normal range or judged by the investigator as not clinically relevant.

Who cannot join the trial?

21 criteria

  • Allergy to finasteride, tadalafil, similar medicines, or any ingredient in the study drugs (known as hypersensitivity).
  • Having rare inherited problems such as galactose intolerance (cannot break down galactose), lactase deficiency (cannot digest lactose), or glucose‑galactose malabsorption (cannot absorb these sugars properly).
  • A history of a serious illness that could affect how the study medicines are absorbed, spread, broken down, or removed from the body, including major surgery (minor surgeries like appendix or gallbladder removal are allowed).
  • Any past or current reason why finasteride or tadalafil should not be taken, or any condition that could be risky after taking these medicines according to their official prescribing information.
  • Veins that are not suitable for repeated blood draws (venipuncture).
  • Any significant illness that occurred within 4 weeks before the first dose.
  • Positive test for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), or HIV, unless you have been vaccinated for hepatitis or had hepatitis that fully resolved.
  • Blood pressure or heart rate outside the normal range when measured after sitting for 5 minutes (systolic 100‑139 mmHg, diastolic 60‑90 mmHg, heart rate 50‑100 beats per minute).
  • Body temperature not between 35.9 °C and 37.5 °C at the screening visit.
  • Experiencing orthostatic hypotension (a drop in blood pressure when standing) during screening or having it in your medical history.
  • Having a serious mental illness or being unable to cooperate with the study team.
  • Abuse of drugs, alcohol (40 g or more of pure ethanol per day), solvents, caffeine, or smoking.
  • Regular use of any medication; vitamins and food supplements may be allowed at the investigator’s discretion before the first dose.
  • Use of drugs that can damage major organs (organ‑toxic drugs) within 3 months before the first dose.
  • Taking multiple doses of medicines that change liver metabolism (hepatic metabolism) within 30 days before the first dose.
  • Taking any prescription medication (by pill, injection, etc.) within 28 days before the first dose.
  • Taking any over‑the‑counter (OTC) medicine, herbal product, or receiving a vaccination within 14 days before the first dose.
  • Donating or losing a large amount of blood or plasma: 500 mL or more within 90 days, more than 150 mL within 30 days, or plasma/platelets within 14 days before the first dose.
  • Participating in another study that used an investigational medical device within 60 days before the first dose.
  • Having taken another investigational drug in a clinical trial within 60 days before the first dose.
  • Any other reason the investigator believes makes participation unsuitable.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • CIALIS

    is a medication that contains tadalafil, which is used to relax blood vessels and increase blood flow. In this study, it was given to healthy volunteers to see how it is absorbed when taken alone and when taken together with another drug.

  • PROSCAR

    is a medication that contains finasteride, which works by reducing the production of certain hormones. In this trial, it was given to healthy volunteers to evaluate how it is absorbed on its own and how its absorption may change when taken together with tadalafil.

What is already known about the treatment

  • CIALIS 5 mg film-coated tablets

    The medication is taken by mouth as a film‑coated tablet that is swallowed whole. It is an approved drug that has been studied extensively and appears in standard medical references. It is mainly used to treat erectile dysfunction by helping improve blood flow to the penis. It works by blocking the enzyme phosphodiesterase‑5, which raises levels of a signal called cGMP that relaxes smooth muscle, and it belongs to the class of phosphodiesterase‑5 inhibitors.

  • PROSCAR 5 mg film-coated tablets

    The medication is taken by mouth as a film‑coated tablet that is swallowed whole. It is an approved drug with a long history of use and many published studies. It is mainly used to treat an enlarged prostate (benign prostatic hyperplasia) and can also help with hair loss. It works by inhibiting the enzyme 5‑alpha‑reductase, which lowers the amount of a hormone called dihydrotestosterone, and it belongs to the class of 5‑alpha‑reductase inhibitors.

Investigated diseases

  • Benign prostatic hyperplasia

    A non‑cancerous enlargement of the prostate gland that develops slowly with age, often causing increased urinary frequency, urgency, a weak stream, and a feeling of incomplete bladder emptying. The prostate continues to grow over months to years, which can progressively worsen these urinary symptoms.

  • Erectile dysfunction

    The persistent difficulty in achieving or maintaining an erection sufficient for satisfactory sexual activity. The condition may arise gradually due to vascular, neurological, hormonal, or psychological factors and can become more frequent over time.

Trial detailsLast updated 16 Nov 2026
Age18+ yearsPhasePhase ITrial ID2024-510774-24-00Estimated enrolment30 patientsSponsorAdamed Pharma S.A.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.